Search clinical trials for: Factor VIII-Fc Fusion Protein

Total 54542 results

RenJi Hospital

Recruiting

Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.

Overall Survival | Progression Free Survival | Maintenance

China
Peking University People's Hospital
Qingdao Municipal Hospital

Recruiting

Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement (SPODUMENE)

Multiple Myeloma

China
Gustave Roussy, Cancer Campus, Grand Paris
Innovative Therapies For Children with Cancer Consortium; Chimerix

Recruiting

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 (BIOMEDE 2)

Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant

France
Irene Ghobrial, MD
Janssen Research & Development, LLC

Recruiting

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Multiple Myeloma | Smoldering Multiple Myeloma | High-risk Smoldering Multiple Myeloma

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Renal Cell Carcinoma

United States, Australia, Israel
St. Jude Children's Research Hospital

Recruiting

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Hepatocellular Carcinoma | Pediatric Cancer | Malignant Solid Tumor | Fibrolamellar Carcinoma | Pediatric Solid Tumor | Refractory Solid Tumor

United States
Shandong University
The Affiliated Hospital of Qingdao University; Qianfoshan Hospital; The Second...

Recruiting

Antineoplastic Drugs in Elderly Patients

Cancer

China
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (MonumenTAL-3)

Relapsed or Refractory Multiple Myeloma

United States, Italy, Korea, Republic of, Taiwan, China, Germany, Turkey, Japan, France, United Kingdom, Brazil, Spain, Czechia, Poland, Israel, Belgium, Greece, Netherlands
Rajshekhar Chakraborty, MD
Genentech, Inc.

Recruiting

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

AL Amyloidosis

United States
First Affiliated Hospital of Zhejiang University

Not yet recruiting

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

Advanced Biliary Tract Carcinoma

China
Zhejiang Provincial People's Hospital

Recruiting

Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

Rheumatoid Arthritis | Treatment Compliance | Abatacept

China
Chiayi Christian Hospital

Recruiting

Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty

Arthroplasty | Venous Thromboembolism

Taiwan
West China Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8

United States
University of Pennsylvania

Recruiting

CART-38 in Adult AML and MM Patients

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM)

United States
Peking University People's Hospital
CASI Pharmaceuticals, Inc.

Recruiting

Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM

Multiple Myeloma

China
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab

Multiple Myeloma

Korea, Republic of, Russian Federation, Spain, Germany, Belgium, Denmark, Greece, France, United States, Ukraine, Poland
RenJi Hospital
The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaborators

Recruiting

PVd Versus Vd in NDMM Patients With RI

Multiple Myeloma

China
AHS Cancer Control Alberta
Tom Baker Cancer Centre

Recruiting

Pilot Trial for Treatment of Recurrent Glioblastoma

Glioblastoma | Recurrent Glioblastoma | Recurrent Disease

Canada
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

HER2+ Breast Cancer

China
First Affiliated Hospital of Wenzhou Medical University

Recruiting

The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.

Diffuse Large B Cell Lymphoma

China
Vascular Therapies, Inc.

Recruiting

A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery (ACCESS2)

End Stage Renal Disease | ESRD | End Stage Kidney Disease | Arteriovenous Fistula | Vascular Access Complication | Chronic Kidney Failure | Complication of Hemodialysis | Complication of Renal Dialysis

United States, United Kingdom
Xia Zhongjun
Antengene Corporation

Recruiting

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
University of Nottingham
University of Oxford

Recruiting

Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune) (Rapamune)

Muscle Atrophy | Age-Related Sarcopenia

United Kingdom
Mayo Clinic

Recruiting

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma | Locally Advanced Pancreatic Carcinoma

United States, Canada
Sun Yat-sen University

Recruiting

Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)

Advanced Biliary Tract Cancer

China
University Hospital, Tours

Not yet recruiting

Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients (CARD-AXA)

Chronic Hemodialysis Patients
The Third Xiangya Hospital of Central South University

Recruiting

Efficacy and Safety Study of Egg Yolk Antibody in Adjuvant Treatment of Helicobacter Pylori Infection

Helicobacter Pylori Infection

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Recruiting

Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML

Core Binding Factor Acute Myeloid Leukemia

China
Mayo Clinic
Ottawa Heart Institute Research Corporation

Recruiting

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)

Radial Artery Occlusion

United States
National Taiwan University Hospital
National Health Research Institutes, Taiwan

Recruiting

Cancer Fusion Hybrids and Desmoplasia

Bone Marrow Cells | Fusion Protein Expression

Taiwan
Jennifer Eva Selfridge

Recruiting

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Colorectal Cancer | Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Plasma Cell Myeloma | Hematologic Malignancy | Rectum Cancer | Myeloproliferative Syndrome

United States
Pfizer

Recruiting

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Breast Cancer

Japan
Peking University

Recruiting

R-MTX-zanbrutinib in Secondary CNS Lymphoma

Secondary Central Nervous System Lymphoma

China
Qingdao Central Hospital

Recruiting

Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial

Overall Survival

China
Mayo Clinic

Recruiting

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Richter Syndrome

United States
Scripps Health

Recruiting

Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia

Hairy Cell Leukemia

United States
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France; W.L.Gore & Associates; Abbott; Centre Hospitalier St... and other collaborators

Not yet recruiting

PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (CLOSE-2)

Patent Foramen Ovale | Cryptogenic Ischemic Stroke

France
Antonio Giordano, MD
Cardiff Oncology

Recruiting

Onvansertib + Paclitaxel In TNBC

Breast Cancer | Metastatic Breast Cancer | Inflammatory Breast Cancer | Invasive Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Carcinoma | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Hormone Receptor Negative Breast Carcinoma | Hormone Receptor/Growth Factor...

United States
LanZhou University
Beijing Health Alliance Charitable Foundation

Recruiting

Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma

Multiple Myeloma

China
National Cancer Institute (NCI)

Recruiting

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Malignant Solid Neoplasm

United States
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Not yet recruiting

Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colon Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8

United States
Xijing Hospital

Recruiting

LAAO Versus NOAC in Patients With AF and PCI

Atrial Fibrillation | Percutaneous Coronary Intervention

China
Ruijin Hospital

Recruiting

Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma (R-ICE+X)

Diffuse Large B Cell Lymphoma

China
University of Illinois at Chicago

Recruiting

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma (HEME-18)

Multiple Myeloma

United States

Search clinical trials for: Factor VIII-Fc Fusion Protein

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations